Status: Recruiting
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
The primary objective of this trial is to evaluate ovarian suppression following treatment with ZOLADEX 10.8 mg by luteinizing hormone (LH) within each cohort.
Participants needed: 176
Trial details
Phase: Phase 1Age: 18-55Biological sex: FemaleType: InterventionalSponsor: TerSera Therapeutics LLCUpdated: Oct 13, 2026Locations: 26
Eligibility criteria
Age and gender: Female participants aged 18 to 55 years, inclusive. [+30]
Postmenopausal: Naturally or surgically postmenopausal (regardless of age). [+27]